Fractyl Health Announces Pricing of $60 Million Underwritten Offering of Common Stock
Fractyl Health (NASDAQ:GUTS), a metabolic therapeutics company specializing in treatments for obesity and type 2 diabetes, has announced the pricing of an underwritten public offering of 60 million shares of common stock at $1.00 per share.
The company expects to raise $60 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses. The offering is anticipated to close around September 29, 2025. BofA Securities and Evercore ISI are serving as joint book-running managers, with Ladenburg Thalmann acting as lead manager.
Fractyl Health (NASDAQ:GUTS), un'azienda di terapie metaboliche che si occupa di trattamenti per obesità e diabete di tipo 2, ha annunciato la determinazione del prezzo di un'offerta pubblica sottoscritta di 60 milioni di azioni ordinarie a $1,00 per azione. La società prevede di raccogliere circa $60 milioni di proventi lordi prima delle detrazioni per sconti di sottoscrizione, commissioni e spese dell'offerta. Si prevede che l'offerta si chiuda intorno al 29 settembre 2025. BofA Securities ed Evercore ISI agiscono come joint book-running managers, con Ladenburg Thalmann in veste di lead manager.
Fractyl Health (NASDAQ:GUTS), una empresa de terapias metabólicas especializada en tratamientos para la obesidad y la diabetes tipo 2, ha anunciado el precio de una oferta pública suscrita de 60 millones de acciones ordinarias a $1.00 por acción. La empresa espera obtener $60 millones de ingresos brutos antes de deducir descuentos de suscripción, comisiones y gastos de la oferta. Se espera que la operación cierre alrededor del 29 de septiembre de 2025. BofA Securities y Evercore ISI actúan como gerentes conjuntos de libro, con Ladenburg Thalmann como gerente líder.
Fractyl Health(NASDAQ:GUTS), 비만과 제2형 당뇨병 치료를 전문으로 하는 대사 치료제 회사는 6천만주의 보통주를 주당 1.00달러에 공모하는 공모 가격 책정을 발표했습니다. 회사는 수수료, 커미션, 발행 비용을 차감하기 전으로 6천만 달러의 총수입을 기대하고 있습니다. 공모는 2025년 9월 29일경에 마감될 것으로 예상됩니다. BofA Securities와 Evercore ISI가 공동 북런닝 매니저로 활동하며, Ladenburg Thalmann이 리드 매니저로 참여합니다.
Fractyl Health (NASDAQ:GUTS), une société de thérapies métaboliques spécialisée dans les traitements contre l'obésité et le diabète de type 2, a annoncé le prix d'une offre publique souscrite de 60 millions d'actions ordinaires à 1,00 $ par action. La société prévoit d'atteindre environ 60 millions de dollars de produits bruts avant déduction des réductions d'émission, des commissions et des frais d'offre. L'offre devrait être clôturée vers le 29 septembre 2025. BofA Securities et Evercore ISI agissent en tant que gérants dépositaires communs, Ladenburg Thalmann agissant en tant que gérant principal.
Fractyl Health (NASDAQ:GUTS), ein Unternehmen für metabolische Therapeutika, das sich auf Behandlungen von Fettleibigkeit und Typ-2-Diabetes spezialisiert hat, hat die Preisgestaltung eines unter Begleitung stehenden öffentlichen Angebots von 60 Millionen Stammaktien zu 1,00 $ pro Aktie bekannt gegeben. Das Unternehmen erwartet brutto Einnahmen von 60 Millionen Dollar vor Abzug von Emissionsrabatten, Provisionen und Emissionsausgaben. Das Angebot soll voraussichtlich am 29. September 2025 geschlossen werden. BofA Securities und Evercore ISI fungieren als gemeinsame Buchrunning-Manager, Ladenburg Thalmann als Lead Manager.
Fractyl Health (NASDAQ:GUTS)، شركة العلاجات الأيضية المتخصصة في علاجات السمنة والسكري النوع 2، أعلنت عن تسعير عرض عام مدعوم من المُكتتبين لــ 60 مليون سهم من الأسهم العادية بسعر $1.00 للسهم. تتوقع الشركة أن تجمع نحو $60 مليون من العائدات الإجمالية قبل خصم خصومات الاكتتاب والعمولات ونفقات العرض. من المتوقع أن يغلق العرض نحو 29 سبتمبر 2025. تعمل BofA Securities وEvercore ISI كمديرين مشتركين للكتاب، بينما تتولى Ladenburg Thalmann مهمة المدير الرئيسي.
Fractyl Health (NASDAQ:GUTS)，一家专注于肥胖和2型糖尿病治疗的代谢疗法公司，宣布以每股1.00美元价格定价一项承销的公开发行，共6000万股普通股。公司预计在扣除承销折扣、佣金和发行业务费用前将募集大约6000万美元毛收益。该发行预计将在2025年9月29日左右完成。BofA Securities与Evercore ISI担任联合账簿管理人，Ladenburg Thalmann担任主承销商。
- Expected gross proceeds of $60 million to strengthen balance sheet
- Support from major investment banks as underwriters indicating institutional backing
- Significant dilution to existing shareholders with 60 million new shares
- Low offering price of $1.00 per share suggests challenging market conditions
Insights
Fractyl raises $60M through stock offering at $1.00/share, likely diluting existing shareholders while securing vital operational runway.
Fractyl Health's $60 million common stock offering presents a significant capital raise for this metabolic therapeutics company. The pricing at
The involvement of major underwriters BofA Securities and Evercore ISI adds credibility to the transaction, though their participation comes with underwriting fees that will reduce the net proceeds below the
For a clinical-stage biotech company, securing this level of funding is strategically important, especially given current market conditions. The capital should help Fractyl advance its pipeline through critical development milestones, though the dilution impact indicates the company's current need for cash outweighs concerns about share price and ownership structure. The shelf registration declared effective in March 2025 provided the regulatory framework for this capital raise, allowing Fractyl to act when market conditions aligned with their financing needs.
Fractyl Health Announces Pricing of
BURLINGTON, Mass., September 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of
BofA Securities and Evercore ISI are acting as joint book-running managers and Ladenburg Thalmann is acting as lead manager for the underwritten offering.
A shelf registration statement relating to the securities offered in the offering described above was filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025, and declared effective by the SEC on March 18, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: dg.prospectus_requests@bofa.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the timing, size, terms and completion of the Company’s underwritten offering. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Fractyl’s business are described in detail in its SEC filings, including in Fractyl’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Fractyl makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Fractyl disclaims any obligation to update these statements except as may be required by law.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
BURLINGTON, Mass., Sept. 26, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company” or “Fractyl”), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (“T2D”), today announced the pricing of an underwritten offering of 60 million shares of its common stock at a price of
BofA Securities and Evercore ISI are acting as joint book-running managers and Ladenburg Thalmann is acting as lead manager for the underwritten offering.
A shelf registration statement relating to the securities offered in the offering described above was filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2025, and declared effective by the SEC on March 18, 2025. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and available on the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting: BofA Securities, NC1-022-02-25, 201 North Tryon Street, Charlotte, North Carolina 28255, Attention: Prospectus Department or by email: dg.prospectus_requests@bofa.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. The Company has a robust and growing IP portfolio, with 33 granted U.S. patents and approximately 40 pending U.S. applications, along with numerous foreign issued patents and pending applications. Fractyl is based in Burlington, MA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” “plans,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the timing, size, terms and completion of the Company’s underwritten offering. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Fractyl’s business are described in detail in its SEC filings, including in Fractyl’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that Fractyl makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Fractyl disclaims any obligation to update these statements except as may be required by law.
Contacts
Media Contact
Jessica Cotrone, Head of Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Brian Luque, Head of Investor Relations and Corporate Development
IR@fractyl.com, 951.206.1200
FAQ
What is the size and price of Fractyl Health's (GUTS) stock offering in September 2025?
When will Fractyl Health's (GUTS) stock offering close?
Who are the underwriters for Fractyl Health's (GUTS) September 2025 offering?
How will Fractyl Health (GUTS) use the proceeds from the stock offering?
